Screener
Palvella Therapeutics PVLA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $263,759 | $59,559 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,443 | $4,595 |
| Derivative liabilities – contingent value right liability | — | 2,196 |
| Current portion of operating lease liability | 209 | 202 |
| Accrued expenses and other current liabilities | 3,463 | 4,351 |
| Total current liabilities | 9,115 | 11,344 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's accounts payable?
- Palvella Therapeutics (PVLA) reported accounts payable of $5.44M in Q1 2026.
- How has Palvella Therapeutics's accounts payable changed year-over-year?
- Palvella Therapeutics's accounts payable increased by 22.6% year-over-year, from $4.44M to $5.44M.
- What is the long-term trend for Palvella Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Palvella Therapeutics's accounts payable has grown at a 20.8% compound annual growth rate (CAGR), from $1.79M to $4.6M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Palvella Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude